Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases

NV Smadja, C Fruchart, F Isnard, C Louvet, JL Dutel… - Leukemia, 1998 - nature.com
We report the cytogenetic results obtained in 81 multiple mye-loma (MM) patients with
abnormal karyotypes. Most karyotypes were complex with numerical and structural …

Systemic capillary leak syndrome: report on 13 patients with special focus on course and treatment

Z Amoura, T Papo, J Ninet, PY Hatron… - The American journal of …, 1997 - Elsevier
BACKGROUND: Systemic capillary leak syndrome (SCLS) is a rare condition characterized
by unexplained episodic capillary hyperpermeability due to a shift of fluid and protein from …

Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemias

JM Boles, P Mialon, M Garre, JL Dutel… - Cancer, 1984 - Wiley Online Library
The authors report a documented case of hyperphosphatemia‐induced nephrocalcinosis
after chemotherapy of an acute lymphoblastic leukemia (ALL). Microscopic examination of …

CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 cases

G Cartron, C Linassier, JL Bremond… - Leukemia & …, 1998 - Taylor & Francis
Chronic lymphocytic leukemia cell (CLL) usually (95%) express B-phenotype and the CD5
antigen which is usually present on the surface of normal T cells. However, among B CLL, 7 …

Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with …

P Pautier, A Rey, C Haie-Meder, P Kerbrat… - International Journal of …, 2004 - ijgc.bmj.com
Uterine sarcoma is a poor prognosis disease, with a high risk of metastatic relapse. We
conducted a study of adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin …

Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques

NV Smadja, C Louvet, F Isnard… - British journal of …, 1995 - Wiley Online Library
Cytogenetic studies in multiple myeloma (MM) have been disappointing due to the low
mitotic index of plasma cells. Recently the detection of clonal chromosomal abnormalities at …

High molecular response rate of polycythemia vera patients treated with pegylated interferon α–2a

JJ Kiladjian, B Cassinat, P Turlure, N Cambier… - Blood, 2006 - ashpublications.org
Abstract V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV),
potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of …

Insulin autoimmune syndrome revealing systemic lupus erythematosus

S Rouabhia, J Ramanoelina, P Godmer… - Annales de Medecine …, 2003 - europepmc.org
A 22-year-old woman was admitted in August 2001 for loss of consciousness due to
hypoglycemia. Her serum insulin level during the hypoglycemic episode was high at 121 …

[HTML][HTML] FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic …

M Hebbar, B Chibaudel, T André, L Mineur, D Smith… - Annals of …, 2015 - Elsevier
The sequential FOLFOX7–FOLFIRI combination is not superior to FOLFOX4 in colorectal
cancer patients with resectable metastases. Patients with synchronous metastases …

[HTML][HTML] Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon α-2a (peg-IFNα-2a) therapy …

P Turlure, N Cambier, M Roussel, S Bellucci, JM Zini… - Blood, 2011 - Elsevier
Abstract Abstract 280 Background: Two phase 2 studies have recently shown promising
results of peg-IFNα-2a therapy in PV and essential thrombocythemia, including major …